Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?
作者信息
Sardana Kabir, Gupta Aastha
机构信息
Department of Dermatology, Dr. Ram Manohar Lohia Hospital, New Delhi, India. E-mail:
出版信息
Indian J Dermatol. 2017 Nov-Dec;62(6):665-667. doi: 10.4103/ijd.IJD_435_17.
Abstract
摘要
相似文献
1
Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD?在顽固性皮肤癣菌病背景下特比萘芬药物剂量测定及疗程的合理性：500毫克每日一次（OD）是否优于250毫克每日一次或每日两次（BD）？
Indian J Dermatol. 2017 Nov-Dec;62(6):665-667. doi: 10.4103/ijd.IJD_435_17.
2
Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis.特比萘芬每日一次500毫克治疗皮肤癣菌病患者的疗效和安全性
Indian J Dermatol. 2017 Jul-Aug;62(4):395-399. doi: 10.4103/ijd.IJD_191_17.
3
Comparison of two systemic antifungal agents, itraconazole and terbinafine, for the treatment of dermatophytosis in European hedgehogs (Erinaceus europaeus).两种全身用抗真菌药物伊曲康唑和特比萘芬治疗欧洲刺猬（ Erinaceus europaeus ）皮肤癣菌病的比较
Vet Dermatol. 2016 Dec;27(6):500-e133. doi: 10.1111/vde.12378. Epub 2016 Sep 12.
4
Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model.特比萘芬与拉康唑和卢立康唑治疗豚鼠皮肤癣菌病的疗效比较。
Med Mycol. 2010 May;48(3):491-7. doi: 10.3109/13693780903373811.
5
Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model.盐酸特比萘芬指甲溶液局部治疗豚鼠皮肤癣菌病疗效的测定
Mycoses. 2009 Jan;52(1):35-43. doi: 10.1111/j.1439-0507.2008.01540.x. Epub 2008 May 21.
6
Efficacy of Topical Therapy with Newly Developed Terbinafine and Econazole Formulations in the Treatment of Dermatophytosis in Cats.新开发的特比萘芬和益康唑制剂局部治疗猫皮肤癣菌病的疗效
Pol J Vet Sci. 2016 Sep 1;19(3):535-543. doi: 10.1515/pjvs-2016-0067.
7
Treatment of shelter cats with oral terbinafine and concurrent lime sulphur rinses.用口服特比萘芬和同时进行的石硫合剂冲洗治疗庇护所猫。
Vet Dermatol. 2013 Dec;24(6):618-20, e149-50. doi: 10.1111/vde.12069. Epub 2013 Aug 23.
8
Terbinafine susceptibility and genotypic heterogeneity in clinical isolates of Trichophyton mentagrophytes by random amplified polymorphic DNA (RAPD).通过随机扩增多态性DNA（RAPD）分析须癣毛癣菌临床分离株的特比萘芬敏感性及基因型异质性
J Mycol Med. 2015 Mar;25(1):e1-9. doi: 10.1016/j.mycmed.2014.09.001. Epub 2015 Jan 30.
9
Relapse after Oral Terbinafine Therapy in Dermatophytosis: A Clinical and Mycological Study.口服特比萘芬治疗皮肤癣菌病后的复发：一项临床和真菌学研究。
Indian J Dermatol. 2016 Sep-Oct;61(5):529-33. doi: 10.4103/0019-5154.190120.
10
Itraconazole and terbinafine in perspective. From petri dish to patient.伊曲康唑和特比萘芬的展望。从培养皿到患者。
Postgrad Med. 1999 Jul;Spec No:6-11.
引用本文的文献
1
, an Emerging Drug-Resistant Dermatophyte: A Review of the Treatment Options.一种新兴的耐药皮肤癣菌：治疗选择综述
J Clin Med. 2024 Jun 18;13(12):3558. doi: 10.3390/jcm13123558.
2
Therapeutic Updates on the Management of Tinea Corporis or Cruris in the Era of : Separating Evidence from Hype-A Narrative Review.时代背景下体癣或股癣治疗的最新进展：区分证据与炒作——一篇叙述性综述
Indian J Dermatol. 2023 Sep-Oct;68(5):525-540. doi: 10.4103/ijd.ijd_832_23.
3
Real World Analysis of Response Rate and Efficacy of Oral Ketoconazole in Patients with Recalcitrant Tinea Corporis and Cruris.口服酮康唑治疗顽固性体股癣的疗效和应答率的真实世界分析。
Am J Trop Med Hyg. 2021 Oct 11;106(1):38-44. doi: 10.4269/ajtmh.21-0505.
4
The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options.前所未有的皮肤病癣菌病流行态势：III. 抗真菌药物耐药性和治疗选择。
Indian J Dermatol Venereol Leprol. 2021;87(4):468-482. doi: 10.25259/IJDVL_303_20.
5
Correlation of Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris.基于 MICs 和角鲨烯环氧化酶突变与特比萘芬治疗体股癣患者临床应答的相关性。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01038-18. Print 2018 Dec.
本文引用的文献
1
Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis.特比萘芬每日一次500毫克治疗皮肤癣菌病患者的疗效和安全性
Indian J Dermatol. 2017 Jul-Aug;62(4):395-399. doi: 10.4103/ijd.IJD_191_17.
2
Clinical presentation of terbinafine-induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic.特比萘芬致严重肝损伤的临床表现及实验室监测的价值：一项批判性评价课题。
Br J Dermatol. 2017 Nov;177(5):1279-1284. doi: 10.1111/bjd.15854. Epub 2017 Oct 11.
3
Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.特比萘芬联合其他抗真菌药物治疗耐药或难治性真菌感染：应用生理基于药代动力学模型探索最佳给药方案。
Antimicrob Agents Chemother. 2014;58(1):48-54. doi: 10.1128/AAC.02006-13. Epub 2013 Oct 14.
4
Terbinafine pharmacokinetics after single dose oral administration in the dog.犬单次口服给药后特比萘芬的药代动力学。
Vet Dermatol. 2011 Dec;22(6):528-34. doi: 10.1111/j.1365-3164.2011.00985.x. Epub 2011 May 20.
5
Update on terbinafine with a focus on dermatophytoses.特比萘芬更新：重点关注皮肤癣菌病。
Clin Cosmet Investig Dermatol. 2009 Apr 21;2:49-63. doi: 10.2147/ccid.s3690.
6
Bilateral anterior optic neuropathy associated with use of terbinafine.与使用特比萘芬相关的双侧前部视神经病变。
Clin Exp Ophthalmol. 2008 Jul;36(5):488-9. doi: 10.1111/j.1442-9071.2008.01795.x.
7
Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic type tinea pedis.口服特比萘芬治疗角化过度型足癣的有效性及药代动力学研究
Mycoses. 2008 Jan;51(1):7-13. doi: 10.1111/j.1439-0507.2007.01438.x.
8
An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis.口服伊曲康唑脉冲疗法与特比萘芬脉冲疗法治疗甲真菌病的开放性随机对照研究
Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):262-6. doi: 10.4103/0378-6323.16619.
9
Clinical utility of antifungal pharmacokinetics and pharmacodynamics.抗真菌药物的药代动力学和药效学的临床应用。
Curr Opin Infect Dis. 2004 Dec;17(6):533-40. doi: 10.1097/00001432-200412000-00005.
10
Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days.每日口服250毫克特比萘芬，持续7天和14天期间及之后，血浆、角质层、真皮-表皮（不包括角质层）、皮脂、毛发和指甲中的特比萘芬水平。
Clin Exp Dermatol. 1994 Mar;19(2):121-6. doi: 10.1111/j.1365-2230.1994.tb01138.x.
Zotero 插件